Medical researchers have shown that by targeting SLC7A11, a cystine transporter, it is possible to starve pancreatic cancer cells and, at the same time, disable cancer-associated fibroblasts that are known to generate dense scar tissue around pancreatic tumors and to block the delivery of chemotherapeutics. Experiments in mouse models suggest that the dual approach could overcome the aggressiveness and drug resistance of pancreatic cancer.